CN105663391A

CN105663391A - Method for preparing Chinese herbal preparation for treating chronic cardiac failure

Info

Publication number: CN105663391A
Application number: CN201610086308.1A
Authority: CN
Inventors: 郭丹丹; 于思明
Original assignee: Heilongjiang University of Chinese Medicine
Current assignee: Heilongjiang University of Chinese Medicine
Priority date: 2016-02-16
Filing date: 2016-02-16
Publication date: 2016-06-15

Abstract

The invention provides a method for preparing a Chinese herbal preparation for treating chronic cardiac failure. The preparation is prepared from radix ginseng rubra, radix aconiti lateralis preparata, radix paeoniae alba, Chinese magnoliavine fruit, poria cocos and polyporus through supercritical extraction, alcohol extraction and water decoction. The preparation can warm heart yang, disperse blood stasis and promote urination and improve myocardial energy metabolism remarkably, and has a remarkable treatment effect on chronic cardiac failure. Meanwhile, through optimization of the preparing process, the content of active ingredients in the Chinese herbal preparation is increased, a definite quality standard can be established, and a research foundation is provided for subsequent industrial production.

Description

A kind of preparation method of Chinese medicine preparation of chronic heart failure

Technical field

The present invention relates to a kind of preparation method of Chinese medicine preparation of chronic heart failure, belong to Chinese medicine application.

Background technology

(chronicheartfailure, CHF) in heart failure is the final home to return to of most angiocardiopathies, is also the topmost cause of death of cardiovascular patient. Heart failure is to be a kind of clinical syndrome due to myocardial failure because myocardial contractive power declines, clinically taking pulmonary circulation and (or) congestion of systemic circulation and perfused tissue deficiency as principal character. Patient's life and quality of life in not only serious threat in heart failure, and its very long treatment cycle and high medical expense have brought white elephant to especially society and family. Thereby how to reduce the patients with heart failure death rate, reducing the number of times of being in hospital is two hang-ups of clinical position. The traditional medicine of heart failure comprises diuretics, vasodilator, positive inotropic medicament, non-Cardiac glycosides positive inotropic medicament etc. Although these medicines have certain curative effect, or because of monitoring, use inconvenience, easily there is bad reaction; Maybe may increase arrhythmia cordis risk; Or only can improve clinical symptoms and be unprofitable to improve late mortality rate, therefore curative effect is not satisfactory. Therefore, how to find more efficiently methods for the treatment of and remain the subject matter facing at present.

Research in recent years shows, in heart failure closely related with energy metabolism of myocardial, the change of myocardium energetics, and to produce, transport and utilize obstacle be the basis of heart failure to cardiac energy, can directly cause the cardiac muscle contracting blood-pumping function obstacle that relaxes.

This seminar is from the Mechanism Study of TCM on Heart Failure, in conjunction with the therapeutic modality of traditional Chinese medical science diversification, develop the flint heart-soothing capsule that can improve energy metabolism of myocardial, " the impact of flint heart-soothing capsule on rats with heart failure after myocardial infarction energy metabolism of myocardial; Guo Dandan etc.; traditional Chinese medicine journal; the 43rd volume; the 2nd phase; 59-61 page that publish thesis of the scientific achievement of gained, 2015 ", the prescription that wherein discloses flint heart-soothing capsule is red ginseng, RADIX ACONITI LATERALIS PREPARATA, the root of herbaceous peony, the fruit of Chinese magnoliavine, Poria cocos, umbellate pore furgus.

In paper publishing process from unexposed consumption and the preparation method who crosses flint heart-soothing capsule each bulk drug. From industrial production viewpoint of measures, weight proportion and the optimized production process of necessary clear and definite bulk drug, just can reach the clear and definite and stable of final curative effect.

Summary of the invention

For solving deficiency of the prior art, the invention provides a kind of preparation method of Chinese medicine preparation of chronic heart failure.

For achieving the above object, on the one hand, the invention provides a kind of Chinese medicine preparation of chronic heart failure, described Chinese medicine all can be concocted according to " national Chinese medicine preparation specification " or " Chinese medicine voluminous dictionary ". Described Chinese medicine preparation is made up of the bulk drug of following parts by weight:

Red ginseng 10-30 part, RADIX ACONITI LATERALIS PREPARATA 15-25 part, root of herbaceous peony 10-20 part, fruit of Chinese magnoliavine 5-15 part, Poria cocos 30-40 part, umbellate pore furgus 20-35 part.

In a preferred embodiment of the present invention, described Chinese medicine preparation is made up of the bulk drug of following weight portion:

Red ginseng 15-25 part, RADIX ACONITI LATERALIS PREPARATA 15-20 part, root of herbaceous peony 10-15 part, fruit of Chinese magnoliavine 5-10 part, Poria cocos 30-40 part, umbellate pore furgus 20-30 part.

In another preferred embodiment of the present invention, described Chinese medicine preparation is made up of the bulk drug of following weight portion:

15 parts of red ginsengs, 20 parts of RADIX ACONITI LATERALIS PREPARATAs, 10 parts of the root of herbaceous peonys, 8 parts, the fruit of Chinese magnoliavine, 35 parts, Poria cocos, 25 parts of umbellate pore furgus.

On the other hand, be used for the treatment of the preparation method of the Chinese medicine preparation of chronic heart failure described in the invention provides:

Described Chinese medicine preparation is to be prepared from by following steps:

(1) take by weight the fruit of Chinese magnoliavine, be ground into 200-300 object fine powder, fruit of Chinese magnoliavine fine powder is joined to CO₂In supercritical extract device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 20-50MPa, temperature 30-55 DEG C, CO₂Flow 10-25L/h, extraction time 1-3h, obtains Fructus Schisandrae Chinensis volatile oil and the dregs of a decoction; Fructus Schisandrae Chinensis volatile oil is dissolved with a small amount of ethanol, separately get the beta-schardinger dextrin-that volatile oil total amount 15-25 doubly measures, the water that adds beta-schardinger dextrin-weight 5-7 doubly to measure grinds well, add therein again Fructus Schisandrae Chinensis volatile oil ethanol lysate, grind to form pasty state, after low temperature drying, obtain Fructus Schisandrae Chinensis volatile oil inclusion compound with ethanolic solution cleaning, drying; The dregs of a decoction are for subsequent use;

(2) take by weight red ginseng, RADIX ACONITI LATERALIS PREPARATA and the root of herbaceous peony, be ground into respectively powder, mixing successively, adds 8-12 and doubly measures 60-95% alcohol reflux extraction 2-4 time, and each 2-4 hour, merges extract, filters, and filtrate recycling ethanol is extremely without alcohol taste, and filtrate and the dregs of a decoction are for subsequent use;

(3) take by weight Poria cocos and umbellate pore furgus, with residue after the fruit of Chinese magnoliavine supercritical extract of gained in step (1), and in step (2) after the alcohol extract of gained residue merge, the water that adds 8-12 doubly to measure, heating decocts 2-4 time, and each 1-3 hour, merges decoction liquor, add the filtrate of gained in step (2), be concentrated into the clear cream that while measurement at 65 DEG C, relative density is 1.15-1.30, dry, pulverize, the powder that gets dry extract, for subsequent use;

(4), the dried cream powder of the Fructus Schisandrae Chinensis volatile oil inclusion compound of step (1) gained and step (3) gained is mixed, stir, be the active component of described Chinese medicine preparation;

(5) step (4) gained active component and auxiliary material are made to pharmaceutically acceptable Chinese medicine preparation.

The formulation of medicine of the present invention is capsule, tablet, powder, oral liquid, soft capsule, pill, tincture, syrup, suppository, gel, spray or injection.

The formulation of medicine of the present invention after weighting raw materials, adopts conventional preparation method's preparation in proportion, and for example, the preparation technology that Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) records, makes the acceptable regular dosage form of pharmacy.

For above-mentioned formulation can be realized, need in the time of these formulations of preparation, add the acceptable auxiliary material of pharmacy, for example: filler, disintegrant, lubricant, suspending agent, adhesive, sweetener, flavouring, anticorrisive agent, matrix etc. Filler comprises: starch, pregelatinized starch, lactose, sweet mellow wine, chitin, microcrystalline cellulose, sucrose etc.; Disintegrant comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, PVPP, low-substituted hydroxypropyl cellulose, Ac-Di-Sol etc.; Lubricant comprises: dolomol, lauryl sodium sulfate, talcum powder, silica etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose etc.; Adhesive comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose etc.; Sweetener comprises: saccharin sodium, aspartame, sucrose, honey element, enoxolone etc.; Flavouring comprises: sweetener and various essence; Anticorrisive agent comprises: parabens, benzoic acid, Sodium Benzoate, sorbic acid and its esters, benzalkonium bromide, acetic acid chloroethene are determined, folium eucalypti wet goods; Matrix comprises: PEG6000, PEG4000, insect wax etc. For making above-mentioned formulation can realize pharmacy of Chinese materia medica, need add acceptable other auxiliary material of pharmacy (Fan Biting " pharmacy of Chinese materia medica ", the auxiliary material that in Shanghai Science Press December in 1997 the 1st edition, each formulation is recorded) when these formulations in preparation.

Effect warming heart yang, stagnation resolvation Li Shui that Chinese medicine preparation of the present invention has, reuses red ginseng benefit gas in side, help less RADIX ACONITI LATERALIS PREPARATA with Wen Yang, again with the root of herbaceous peony, fruit of Chinese magnoliavine nourishing the blood and yin. The root of herbaceous peony, the fruit of Chinese magnoliavine are closed monkshood treating YANG within YIN, close Poria cocos, umbellate pore furgus nourishing YIN and promoting diuresis. By modern medicine study, Chinese medicine preparation of the present invention can obviously improve energy metabolism of myocardial, and chronic heart failure tool is had significant therapeutic effect. Meanwhile, through optimum preparation condition, the active component content of gained Chinese medicine preparation improves, and is conducive to set up clear and definite quality standard, for follow-up suitability for industrialized production provides Research foundation.

Detailed description of the invention

Further describe technical scheme of the present invention by following embodiment. It is pointed out that following explanation is only illustrating of the technical scheme claimed to the present invention, the not any restriction to these technical schemes. The content that protection scope of the present invention is recorded with appended claims is as the criterion.

Embodiment 1:

Bulk drug formula is:

Described Chinese medicine preparation is capsule, is prepared from by following steps:

(1) take by weight the fruit of Chinese magnoliavine, be ground into 200 object fine powders, fruit of Chinese magnoliavine fine powder is joined to CO₂In supercritical extract device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4%, extracting pressure 35MPa, temperature 45 C, CO₂Flow 15L/h, extraction time 3h, obtains Fructus Schisandrae Chinensis volatile oil and the dregs of a decoction; Fructus Schisandrae Chinensis volatile oil is dissolved with a small amount of ethanol, separately get the beta-schardinger dextrin-of 20 times of amounts of volatile oil total amount, add the water of 6 times of amounts of beta-schardinger dextrin-weight to grind well, add therein again Fructus Schisandrae Chinensis volatile oil ethanol lysate, grind to form pasty state, after low temperature drying, obtain Fructus Schisandrae Chinensis volatile oil inclusion compound with ethanolic solution cleaning, drying; The dregs of a decoction are for subsequent use;

(2) take by weight red ginseng, RADIX ACONITI LATERALIS PREPARATA and the root of herbaceous peony, be ground into respectively powder, mixing successively, adds 9 times of amount 85% alcohol refluxs and extracts 3 times, and each 2.5 hours, merge extract, filter, filtrate recycling ethanol is extremely without alcohol taste, and filtrate and the dregs of a decoction are for subsequent use;

(3) take by weight Poria cocos and umbellate pore furgus, with residue after the fruit of Chinese magnoliavine supercritical extract of gained in step (1), and in step (2) after the alcohol extract of gained residue merge, add the water of 10 times of amounts, heating decocts 3 times, each 2 hours, merges decoction liquor, add the filtrate of gained in step (2), be concentrated into the clear cream that while measurement at 65 DEG C, relative density is 1.25, dry, pulverize, the powder that gets dry extract, for subsequent use;

(5), the active component of step (4) gained is added to the lactose of 2 times of amounts, spray into 75% ethanol, granulate, cross 14 mesh sieves, at 70 DEG C, be dried to moisture below 3%, pack in capsulae vacuus, to obtain final product.

Embodiment 2:

Bulk drug formula is:

20 parts of red ginsengs, 15 parts of RADIX ACONITI LATERALIS PREPARATAs, 12 parts of the root of herbaceous peonys, 10 parts, the fruit of Chinese magnoliavine, 30 parts, Poria cocos, 20 parts of umbellate pore furgus.

(1) take by weight the fruit of Chinese magnoliavine, be ground into 300 object fine powders, fruit of Chinese magnoliavine fine powder is joined to CO₂In supercritical extract device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 30MPa, temperature 50 C, CO₂Flow 18L/h, extraction time 1.5h, obtains Fructus Schisandrae Chinensis volatile oil and the dregs of a decoction; Fructus Schisandrae Chinensis volatile oil is dissolved with a small amount of ethanol, separately get the beta-schardinger dextrin-of 18 times of amounts of volatile oil total amount, add the water of 7 times of amounts of beta-schardinger dextrin-weight to grind well, add therein again Fructus Schisandrae Chinensis volatile oil ethanol lysate, grind to form pasty state, after low temperature drying, obtain Fructus Schisandrae Chinensis volatile oil inclusion compound with ethanolic solution cleaning, drying; The dregs of a decoction are for subsequent use;

(2) take by weight red ginseng, RADIX ACONITI LATERALIS PREPARATA and the root of herbaceous peony, be ground into respectively powder, mixing successively, adds 10 times of amount 80% alcohol refluxs and extracts 3 times, and each 3 hours, merge extract, filter, filtrate recycling ethanol is extremely without alcohol taste, and filtrate and the dregs of a decoction are for subsequent use;

(3) take by weight Poria cocos and umbellate pore furgus, with residue after the fruit of Chinese magnoliavine supercritical extract of gained in step (1), and in step (2) after the alcohol extract of gained residue merge, add the water of 9 times of amounts, heating decocts 3 times, each 2.5 hours, merges decoction liquor, add the filtrate of gained in step (2), be concentrated into the clear cream that while measurement at 65 DEG C, relative density is 1.20, dry, pulverize, the powder that gets dry extract, for subsequent use;

Embodiment 3:

Bulk drug formula is:

10 parts of red ginsengs, 22 parts of RADIX ACONITI LATERALIS PREPARATAs, 15 parts of the root of herbaceous peonys, 12 parts, the fruit of Chinese magnoliavine, 40 parts, Poria cocos, 30 parts of umbellate pore furgus.

(1) take by weight the fruit of Chinese magnoliavine, be ground into 300 object fine powders, fruit of Chinese magnoliavine fine powder is joined to CO₂In supercritical extract device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 6%, extracting pressure 45MPa, 35 DEG C of temperature, CO₂Flow 20L/h, extraction time 2.5h, obtains Fructus Schisandrae Chinensis volatile oil and the dregs of a decoction; Fructus Schisandrae Chinensis volatile oil is dissolved with a small amount of ethanol, separately get the beta-schardinger dextrin-of 22 times of amounts of volatile oil total amount, add the water of 7 times of amounts of beta-schardinger dextrin-weight to grind well, add therein again Fructus Schisandrae Chinensis volatile oil ethanol lysate, grind to form pasty state, after low temperature drying, obtain Fructus Schisandrae Chinensis volatile oil inclusion compound with ethanolic solution cleaning, drying; The dregs of a decoction are for subsequent use;

(2) take by weight red ginseng, RADIX ACONITI LATERALIS PREPARATA and the root of herbaceous peony, be ground into respectively powder, mixing successively, adds 12 times of amount 75% alcohol refluxs and extracts 3 times, and each 3 hours, merge extract, filter, filtrate recycling ethanol is extremely without alcohol taste, and filtrate and the dregs of a decoction are for subsequent use;

(3) take by weight Poria cocos and umbellate pore furgus, with residue after the fruit of Chinese magnoliavine supercritical extract of gained in step (1), and in step (2) after the alcohol extract of gained residue merge, add the water of 12 times of amounts, heating decocts 3 times, each 2.5 hours, merges decoction liquor, add the filtrate of gained in step (2), be concentrated into the clear cream that while measurement at 65 DEG C, relative density is 1.30, dry, pulverize, the powder that gets dry extract, for subsequent use;

Comparative example 1

Take Chinese medicine by the parts by weight of 15 parts of red ginsengs, 20 parts of RADIX ACONITI LATERALIS PREPARATAs, 10 parts of the root of herbaceous peonys, 8 parts, the fruit of Chinese magnoliavine, 35 parts, Poria cocos, 25 parts of umbellate pore furgus, add the decocting of 10 times of amounts to boil, decoct 3 times, each 2h, merges decoction liquor, is concentrated into the clear cream that while measurement at 65 DEG C, relative density is 1.25, dry, pulverize, powder gets dry extract, to the lactose that adds 2 times of amounts in dried cream powder, spray into 75% ethanol, granulate, cross 14 mesh sieves, at 70 DEG C, be dried to moisture below 3%, pack in capsulae vacuus, to obtain final product.

Comparative example 2

Take Chinese medicine by the parts by weight of 15 parts of red ginsengs, 20 parts of RADIX ACONITI LATERALIS PREPARATAs, 10 parts of the root of herbaceous peonys, 8 parts, the fruit of Chinese magnoliavine, 35 parts, Poria cocos, 25 parts of umbellate pore furgus, add 10 times of amount 85% alcohol refluxs to extract 3 times, each 3 hours, merge extract, filter, filtrate recycling ethanol is to without alcohol taste, continues to be concentrated into the clear cream that while measurement at 65 DEG C, relative density is 1.25, dry, pulverize, the powder that gets dry extract, to the lactose that adds 2 times of amounts in dried cream powder, spray into 75% ethanol, granulate, cross 14 mesh sieves, at 70 DEG C, be dried to moisture below 3%, pack in capsulae vacuus, to obtain final product.

For confirming the remarkable effect of preparation method of the present invention in performance aspect described Chinese medicine preparation curative effect, use the capsule making by embodiment 1, carry out following animal experiment research:

1 material

1.1 animal used as test

Select 100 of healthy male Wistar rats, body weight 200～240g, is provided by Harbin Medical University's Experimental Animal Center.

1.2 medicines and reagent

Capsule prepared by medicine: embodiment 1.

Control drug: the capsule that the capsule that comparative example 1 makes and comparative example 2 make.

Positive control: Valsartan sheet, produced by Novartis Pharma AG.

Other reagent: atriphos (ATP) kit, adenosine diphosphate (ADP) (ADP) kit builds up Bioengineering Research Institute by Nanjing provides, by Shanghai, good and bio tech ltd provides ATP standard items.

1.3 laboratory apparatus

Electronic analytical balance (plum Teller-Tuo benefit Instrument Ltd.), transmission electron microscope (HIT), H-600 type high performance liquid chromatograph (LC-9A, Shimadzu Electronic Instrument, Limited of Japan), IMS cytological image analyses system (Shanghai Shenteng Information Technology Co., Ltd.), L-400 colorful ultrasonic cardiograph (GE, medicalsystem, the U.S.), Pclab-430C Acquisition and Processing of Biomedical Signal (Beijing Wei Xinsida scientific & technical corporation), 5700 real-time PCRs (ABIAppliedBiosystems, USA); ImageMasterVDS picture system (PharmaciaBiotch company).

2 methods

2.1 model preparations

By rat, with 1% yellow Jackets (30mg/kg) intraperitoneal injection anesthesia, dorsal position is fixed, the conventional preserved skin in chest art district, sterilization. After rats underwent trachea cannula, meet breathing apparatus's (setting tidal volume 3ml/min, 60 times/min of frequency). In the strength of apex beat, (the 4th, 5 intercostal) place parallel with breastbone, top is about the otch of 2cm, and blunt separation pectoralis major, with blunt nosed anodontia curved forceps subsides left border of sternum insertion intercostal muscle, expand chest incision, strip off pericardium, extruding chest, extrudes heart outside thoracic cavity. The rapidly fixing apex of the heart, cut off pericardium, absorbable 6-0 suture with needle ligation for about 1-2mm place under LADCA (LAD) starting point, bleach with the following position of ligation cardiac muscle outward appearance, beat and weaken, standard limb leads II(chart speed 50mm/s) raise >=0.1mV of the ECG ST section back of a bow be acute myocardial infarction AMI (AMI) form. Then heart is resetted, extrude air in thoracic cavity, skin suture. Rats in sham-operated group is performed the operation the same period, and step is the same, separates LAD, through LAD, does not carry out ligation with 6-0 suture with needle. The postoperative penicillin that gives of each group rat prevents to infect.

2.2 group technology

Within after operation 6 weeks, detect Cardiac Function in Rat with L-400 colorful ultrasonic cardiograph, with reference to pertinent literature, be less than 60% using EF value and successfully indicate as modeling. Reject death, do not become mould rat, be divided at random: sham-operation group, model group, Valsartan group, 1 group of embodiment, 1 group of comparative example, 2 groups of comparative examples, 12 every group.

2.3 medication

1 group of embodiment gives dosage 10.8gkg^－1·d^－1Gavage, 1 group of comparative example gives dosage 10.8gkg^－1·d^－1Gavage, 2 groups of comparative examples give dosage 10.8gkg^－1·d^－1Gavage, sham-operation group, model group give equivalent physiological saline gavage, and Valsartan group gives Valsartan 30mgkg^－1·d^－1Gavage, 1 time/d, successive administration 8w.

2.4 haemodynamics and cardiac output detect

6h after last administration, RECA will be separated after rat anesthesia, PE50 vaginula pipe is inserted in puncture, and be connected with Pclab-430C Acquisition and Processing of Biomedical Signal, record rat carotid artery systolic pressure (SAP), diastolic pressure (DAP), heart rate, then sheath pipe is driven in the wrong direction and sends into left ventricle, recording occurring continuously left ventricular systolic pressure (LVSP), left ventricular end diastolic presssure (LVEDP), the maximum rising of left indoor pressure and fall off rate (± dp/dtmax). Rats underwent trachea cannula, connects HX-200 animal respirator, opens chest and separates aorta ascendens. Aortic root is settled electromagnetic flowmeter probe No. 2, is cardiac output (CO) through MFV-320 type electromagnetic flowmeter survey ABF.

2.5 wet heart weight

After rat carotid artery blood sampling, open thoracic cavity, expose heart, dirty heart connective tissue and the heart muscle around that cut off of coring, 0.1mol/LpH7.4 phosphate buffer (PBS) washing of the precooling of processing with DEPC, after filter paper blots, take left and right ventricles flesh weight to analyze Libra, calculate heart/body weight ratio by ventricle weight/body weight.

2.6 cardiac muscular tissue's morphological observations

Cut cardiac muscular tissue of left ventricular ischemia district, be cut into 1mm³Fritter, with normal saline flushing, fixes with 2.5% glutaraldehyde successively, and 1% osmic acid is fixed, Gradient elution using ethanol, and epoxy resin embedding, section, the Ultrastructural change of cardiac muscular tissue is observed in dyeing under transmission electron microscope.

2.7 ATP of cardiac muscular tissue, ADP content detection

2.7.1 sample preparation

Get free wall cardiac muscular tissue of rat left chamber, electronic balance accurately weighs 100mg, add 0.42mol/L perchloric acid 600ul homogenate, the centrifugal 5min of 3000rPmin low temperature (4 DEG C), gets supernatant 200ul and adds 0.1mol/LKOH, adjusting PH is 6.24, vortex mixer mixes, and the centrifugal 15min of low temperature (4 DEG C), gets supernatant 100ul to be measured.

2.7.2 chromatographic condition: chromatographic column: Shim-PackCLC-ODSNo.161519959B; Mobile phase: 220mmol/L potassium phosphate buffer solution, include 10% methyl alcohol, adjust pH to 6.5 with tetrabutylammonium hydroxide amine, all samples and standard sample are all used sample introduction 20ul after the membrane filtration in 0.45um aperture before sample introduction. Detect flow velocity 0.8ml/min, detect wavelength 254nm.

2.8 statistical method

Adopt SPSS13.0 statistics software to carry out statistical analysis, measurement data with (x-± s) represent, between group, relatively use one-way analysis of variance, with p ﹤ 0.05 for there being statistical significance.

3 results

3.1 ordinary circumstance

72 rats that enter intervention at duration of test because of 3 of the former cause deaths such as gavage, in the haemodynamics of being expert at testing process dead 5 (2 of model group, 1 group 1 of embodiment, 1 group 2 of comparative examples).

3.2 hemodynamic indexs detect relatively

After Cheng Mo, respectively organize rat SAP, DAP and raise, increased heart rate, cardiac output declines. Control group SAP, DAP level are lower than model group (p < 0.01); 1 group of SAP level of embodiment is lower than model group (p < 0.05), DAP level and model group comparing difference not statistically significant; 1 group of heart rate of embodiment is lower than model group (p < 0.05), and control group heart rate has reduction trend, but not statistically significant. Control group, 1 group of embodiment, 1 group of cardiac output of comparative example are higher than model group (p < 0.01). In table 1.

The comparison of the each group of table 1 rat carotid artery SAP, DAP and heart rate (x-± s)

Note: with model group comparison, * p < 0.05, * * p < 0.01

After Cheng Mo, respectively organize rat LVSP, LVEDP and raise, ± dp/dtmax declines. Control group, embodiment 1 group of LVSP, LVEDP be lower than model group (p < 0.01), and ± dp/dtmax is higher than model group (p < 0.01), comparing difference not statistically significant between group. In table 2.

The comparison of pressure and rate of change in table 2 Ge Zu rat left chamber (x-± s)

Note: with model group comparison, * p < 0.01

3.3 cardiac muscular tissue's morphological change

Sham-operation group myocardium myo fibrillation marshalling, structure of mitochondria is complete, cardiac muscle cell's no abnormality seen. Model group muscle fibril arrangement disorder, muscle segment, myofilament fracture, intercalated disc structural fuzzy, is and melts the shape that dissociates; Mitochondrial swelling, mitochondrial cristae fracture, part is cavity shape, and cardiac cell nucleus is slight cavitation shape, nuclear membrane structural fuzzy. Valsartan group cardiac cell nucleus ovalize, local myofilament fracture, indivedual mitochondrial cristae fractures, kernel is clear. 1 group of muscle fibril of embodiment is arranged more neat, and muscle segment is clear, mitochondria mild swelling, mitochondrial cristae disorder, part fracture. 2 groups of 1 group of comparative examples, comparative example are similar to model group performance.

3.4 hearts/body weight ratio and the ATP of cardiac muscular tissue, ADP content are in table 3.

The comparison of table 3 each group rat heart/body weight ratio and the ATP of cardiac muscular tissue and ADP content (x-± s)

Note: with model group comparison, * p < 0.01

This result of study shows, adopts following coronary artery occlusion left anterior descending branch to cause Rat of Myocardial Infarction model, and obvious damage can appear in postoperative 6w Cardiac Function in Rat, detects and confirms modeling success through ultrasound cardiograph. According to Related literature analysis, its mechanism may with regional myocardial vascular occlusion, produce energy metabolism of myocardial obstacle because the factor such as ischemic, anoxic stimulates, get muddled relevant at the aspect such as generation and utilization of substrate utilization, injury of mitochondria, atriphos simultaneously. This research is observed, and heart failure following myocardial infarction in rats rat ATP, ADP generate significantly and reduce. ATP is the energy matter that cardiac muscle cell can directly utilize, and in the time of energy metabolism of myocardial obstacle, ATP generates to reduce and exist and utilizes obstacle, causes progress in heart failure. This result of study shows, embodiment 1 capsule and Valsartan all can alleviate the damage of cardiac muscular tissue, improving aspect haemodynamics, and Valsartan has obvious advantage, but improving aspect energy metabolism of myocardial, and embodiment 1 capsule is better than Valsartan.

The foregoing is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of raw material of the present invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.

Claims

1. the Chinese medicine preparation of a chronic heart failure, it is characterized in that, described Chinese medicine preparation is made up of the bulk drug of following parts by weight: red ginseng 10-30 part, RADIX ACONITI LATERALIS PREPARATA 15-25 part, root of herbaceous peony 10-20 part, fruit of Chinese magnoliavine 5-15 part, Poria cocos 30-40 part, umbellate pore furgus 20-35 part;

Preparation method is:

(1) take by weight the fruit of Chinese magnoliavine, be ground into 200-300 object fine powder, fruit of Chinese magnoliavine fine powder is joined to CO₂In supercritical extract device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 20-50MPa, temperature 30-55 DEG C, CO₂Flow 10-25L/h, extraction time 1-3h, obtains Fructus Schisandrae Chinensis volatile oil and the dregs of a decoction; Fructus Schisandrae Chinensis volatile oil is dissolved with a small amount of ethanol, separately get the beta-schardinger dextrin-that volatile oil total amount 15-25 doubly measures, the water that adds beta-schardinger dextrin-weight 5-7 doubly to measure grinds well, add therein again Fructus Schisandrae Chinensis volatile oil ethanol lysate, grind to form pasty state, after low temperature drying, clean with ethanolic solution, be drying to obtain Fructus Schisandrae Chinensis volatile oil inclusion compound, the dregs of a decoction are for subsequent use;

(2) take by weight red ginseng, RADIX ACONITI LATERALIS PREPARATA and the root of herbaceous peony, be ground into respectively powder, mix successively, add the 60-95% alcohol reflux that 8-12 doubly measures and extract 2-4 time, each 2-4 hour, merging extract, filter, filtrate recycling ethanol is extremely without alcohol taste, and filtrate and the dregs of a decoction are for subsequent use;

2. Chinese medicine preparation according to claim 1, it is characterized in that, described Chinese medicine preparation is made up of the bulk drug of following weight portion: red ginseng 15-25 part, RADIX ACONITI LATERALIS PREPARATA 15-20 part, root of herbaceous peony 10-15 part, fruit of Chinese magnoliavine 5-10 part, Poria cocos 30-40 part, umbellate pore furgus 20-30 part.

3. Chinese medicine preparation according to claim 1, is characterized in that, described Chinese medicine preparation is made up of the bulk drug of following weight portion: 15 parts of red ginsengs, 20 parts of RADIX ACONITI LATERALIS PREPARATAs, 10 parts of the root of herbaceous peonys, 8 parts, the fruit of Chinese magnoliavine, 35 parts, Poria cocos, 25 parts of umbellate pore furgus.

4. according to the Chinese medicine preparation described in claim 1-3 any one, it is characterized in that, described Chinese medicine preparation is capsule, tablet, powder, oral liquid.

5. according to a preparation method for the Chinese medicine preparation described in claim 1-3 any one, it is characterized in that: described Chinese medicine preparation is to be prepared from by following steps: